Core Insights - TimesSquare Capital Management reported a gross return of 11.28% and a net return of 11.02% for its "U.S. Small Cap Growth Strategy" in Q2 2025, underperforming the Russell 2000 Growth Index which returned 11.97% [1] - The fund's performance was attributed to double-digit returns in equities driven by global economic activity [1] Company Highlights - Excelerate Energy, Inc. (NYSE:EE) is highlighted as a leading provider of liquefied natural gas (LNG) solutions, with a one-month return of -2.79% and a 52-week gain of 28.15% [2] - As of September 10, 2025, Excelerate Energy's stock closed at $23.72 per share, with a market capitalization of $2.705 billion [2] - The stock saw a 3% increase as profits exceeded expectations for Q1, prompting management to raise full-year guidance [3] Hedge Fund Interest - Excelerate Energy, Inc. was held by 29 hedge fund portfolios at the end of Q2 2025, an increase from 22 in the previous quarter [4] - Despite its potential, some analysts suggest that certain AI stocks may offer greater upside potential and lower downside risk compared to Excelerate Energy [4]

Core Insights - TimesSquare Capital Management reported a gross return of 11.28% and a net return of 11.02% for its "U.S. Small Cap Growth Strategy" in Q2 2025, underperforming the Russell 2000 Growth Index which returned 11.97% [1] - The fund's performance was influenced by double-digit returns in equities due to improved global economic activity [1] Company Overview: Wyndham Hotels & Resorts, Inc. - Wyndham Hotels & Resorts, Inc. (NYSE:WH) is a hotel franchisor with a market capitalization of $6.431 billion, closing at $84.22 per share on September 10, 2025 [2] - The stock experienced a one-month return of -5.13% but gained 8.32% over the last 52 weeks [2] Investment Strategy and Market Position - TimesSquare Capital's investment strategy favors value-oriented or specialty retailers, franchise models, and premium brands, with Wyndham being a key focus [3] - The company lowered its forward guidance due to softening trends in consumer travel, resulting in a 10% decline in stock price, prompting TimesSquare to increase its position [3] Hedge Fund Interest - Wyndham Hotels & Resorts, Inc. was held by 46 hedge fund portfolios at the end of Q2 2025, a decrease from 49 in the previous quarter [4] - Despite acknowledging Wyndham's potential, the company believes that certain AI stocks present greater upside potential with less downside risk [4]

Group 1 - TimesSquare Capital Management's "U.S. Small Cap Growth Strategy" reported a gross return of 11.28% and a net return of 11.02% for Q2 2025, compared to the Russell 2000 Growth Index's return of 11.97% [1] - The fund's performance was attributed to double-digit returns in equities driven by positive global economic activity [1] - Ollie's Bargain Outlet Holdings, Inc. (NASDAQ:OLLI) was highlighted as a key stock, with a one-month return of -1.65% and a 52-week gain of 32.16%, closing at $129.73 per share with a market capitalization of $7.954 billion on September 10, 2025 [2] Group 2 - Ollie's Bargain Outlet Holdings, Inc. reported better-than-expected results, with favorable same-store sales comparisons and successful acquisitions of former Big Lots locations [3] - The number of hedge funds holding Ollie's increased from 25 to 32 in the second quarter, indicating growing interest, although it is not among the 30 most popular stocks among hedge funds [4] - Despite the potential of Ollie's as an investment, some analysts suggest that certain AI stocks may offer greater upside potential with less downside risk [4]

Group 1: Investment Performance - Sound Shore Management's Investor Class (SSHFX) and Institutional Class (SSHVX) delivered returns of 3.06% and 3.10% respectively in Q2 2025, compared to 3.79% for the Russell 1000 Value Index and 10.94% for the S&P 500 [1] - The 35-year annualized returns for SSHFX and SSHVX were 14.92% and 15.14% respectively, outperforming the Russell Value at 12.76% but trailing the S&P 500 at 19.71% as of June 30, 2025 [1] Group 2: The Walt Disney Company (NYSE:DIS) - The Walt Disney Company had a one-month return of -0.45% and a 52-week gain of 29.66%, with a stock price of $115.79 and a market capitalization of $208.182 billion as of September 10, 2025 [2] - Sound Shore Management views The Walt Disney Company as an attractive investment due to its successful repositioning and plans to launch the ESPN streaming service by the end of 2025, indicating potential for growth both domestically and internationally [3] - Despite the potential of The Walt Disney Company, some analysts suggest that certain AI stocks may offer greater upside potential and less downside risk, with 111 hedge fund portfolios holding Disney shares at the end of Q2 2025, up from 104 in the previous quarter [4]

Core Insights - Corcept Therapeutics Inc. has revised its 2025 revenue guidance to $850-$900 million, down from $900-$950 million, but management remains confident in growth due to an expanded sales force, new pharmacy partnerships, and pipeline progress [1][2] - The potential of relacorilant is emphasized, with a projected annual revenue of $3-$5 billion in hypercortisolism alone, and a PDUFA date set for December 30, 2025 [2] - The company has established a dedicated oncology division to prepare for the commercialization of relacorilant, which is expected to launch quickly if approved [2][3] - Additional studies are being conducted in various cancer settings and other indications, with a second pharmacy expected to enhance revenue growth starting Q4 2023 [3] Financial Performance - Corcept's stock has doubled over the past year, with analysts projecting another 100% return over the next 12 months, all assigning a Buy or equivalent rating [4] - The company is focused on treating severe endocrinologic, oncologic, metabolic, and neurologic disorders through cortisol modulation [4]

Core Viewpoint - Gossamer Bio Inc. (NASDAQ:GOSS) is highlighted as a promising multibagger stock, primarily due to its lead asset, Seralutinib, which targets pulmonary arterial hypertension (PAH) [1] Group 1: Stock Performance - The stock has seen significant growth, rising from approximately $1 at the beginning of the year to $2.50, resulting in nearly 180% returns year-to-date [1] - Analyst sentiment has strengthened, with a Buy rating from Piper Sandler and a price target of $15 reiterated [2] - H.C. Wainwright also reaffirmed a Buy rating with a target of $10, indicating confidence in Seralutinib [3] Group 2: Drug Development and Trials - Recent literature reviews and trial extensions have bolstered optimism around Seralutinib, with Phase 2 study data showing benefits sustained for 72 weeks, including reduced pulmonary vascular resistance and improved six-minute walk distance [4] - The potential for Seralutinib to be used in combination with other therapies could expand its application in pulmonary treatment [5] - The upcoming Phase 3 PROSERA trial, with results expected in February 2026, is identified as a significant upcoming catalyst for the company [5] Group 3: Company Overview - Gossamer Bio Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for pulmonary and cardiovascular diseases [5]

Company Overview - The Kraft Heinz Company (NASDAQ:KHC) has experienced a 13% decline in share price year-to-date, reflecting a broader bearish sentiment in the food sector [2] - The recent drop in share price was exacerbated by the announcement of a split into two companies, reversing a merger from 2015, which led to a 7% decrease in shares [2] Brand Perception - Concerns have been raised regarding the popularity of Kraft Heinz's brands among younger consumers, with references to the brands being perceived as "old" [2][3] - Cramer highlighted that while some brands like Oscar Mayer have historical significance, they may not resonate with current consumer preferences due to concerns over ingredients [2] Strategic Moves - The company's decision to split aims to revive growth, but there are doubts about the effectiveness of this strategy given the challenges faced in the consumer packaged goods sector [3] - Cramer noted that while there was a time when restructuring could yield positive results, the current grocery landscape presents significant challenges for brands like Kraft, Jello, and Oscar Mayer [3]

Group 1 - lululemon athletica inc. (LULU) shares fell by 18.6% following the second-quarter earnings report, which indicated struggles with tariff impacts [3] - The company's fiscal full-year midpoint earnings per share guidance was set at $12.87, significantly below analyst estimates of $14.45 per share [3] - High pricing strategies are identified as a contributing factor to lululemon's challenges, particularly in competition with lower-priced alternatives like those from Costco [3] Group 2 - Despite the current challenges, there is potential for lululemon as an investment, although some analysts believe AI stocks may offer better returns with lower risk [4]

Core Viewpoint - Jim Cramer has highlighted Costco Wholesale Corporation (NASDAQ:COST) as a strong retail stock, emphasizing its ability to maintain low prices for consumers and its competitive edge against other brands like Lululemon [2][3]. Group 1: Company Performance - Costco's shares have increased by 6.8% year-to-date, recovering from a significant 13% decline in March following the second-quarter earnings report [2]. - The company's former CFO, Richard Galanti, implemented effective price reduction strategies that have contributed to Costco's market position [2][3]. Group 2: Competitive Positioning - Cramer noted that Costco's strategy involves challenging companies that charge high prices, which has proven successful against competitors like Lululemon and Tito's [2]. - The perception of Costco as a formidable competitor is reinforced by Cramer's comments on its ability to win price battles in the retail space [3]. Group 3: Consumer Engagement - Cramer expressed a personal affinity for Costco, indicating that it is a frequent shopping destination for him and his family, which reflects strong consumer loyalty [3]. - The company is recognized for offering significant value, with Cramer describing the Costco shopping experience as one of the best bargains available [3].

Group 1 - The Carillon Scout Mid Cap Fund's second quarter 2025 investor letter indicates that the Russell Midcap Index experienced positive returns despite a sell-off in early April due to tariff announcements, with delays in tariff collection allowing for better negotiations among trading partners [1] - Coca-Cola Consolidated, Inc. (NASDAQ:COKE) was highlighted as a key stock, showing a one-month return of 6.71% but a 52-week loss of 4.78%, with a market capitalization of $10.65 billion as of September 09, 2025 [2] - The fund noted that Coca-Cola Consolidated, Inc. is one of the largest bottlers in the U.S., facing challenges from higher costs but expecting earnings improvement due to strong brand performance [3] Group 2 - Coca-Cola Consolidated, Inc. was held by 37 hedge fund portfolios at the end of the second quarter, an increase from 22 in the previous quarter, indicating growing interest among institutional investors [4] - The analysis suggests that while Coca-Cola Consolidated, Inc. has investment potential, certain AI stocks may offer greater upside with less risk, reflecting a shift in investment focus [4]